These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25142988)

  • 1. [Serum HER2 ECD level and its clinical significance in advanced breast cancer patients with different molecular subtypes].
    Zhou J; Liu Y; Wang T; Zhang H; Du M; Zhang S; Wu S; Song S; Liu B; Zhang H; Jiang Z
    Zhonghua Yi Xue Za Zhi; 2014 May; 94(18):1384-7. PubMed ID: 25142988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
    Lennon S; Barton C; Banken L; Gianni L; Marty M; Baselga J; Leyland-Jones B
    J Clin Oncol; 2009 Apr; 27(10):1685-93. PubMed ID: 19255335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
    Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
    Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
    Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Kahlert S; Stieber P
    Clin Chim Acta; 2014 Mar; 430():86-91. PubMed ID: 24412321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.
    Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A
    J BUON; 2008; 13(3):409-13. PubMed ID: 18979558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
    Lee SB; Lee JW; Yu JH; Ko BS; Kim HJ; Son BH; Gong G; Lee HJ; Kim SB; Jung KH; Ahn JH; Lee W; Sung J; Ahn SH
    BMC Cancer; 2014 Dec; 14():929. PubMed ID: 25491647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer.
    Ma L; Yang HY; Han XH; Li J; Wang F; Zhang CL; Yao JR; Shi YK
    Chin Med J (Engl); 2012 Nov; 125(22):4104-10. PubMed ID: 23158151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.
    Rocca A; Cancello G; Bagnardi V; Sandri MT; Torrisi R; Zorzino L; Viale G; Pietri E; Veronesi P; Dellapasqua S; Ferrucci F; Luini A; Johansson H; Ghisini R; Goldhirsch A; Colleoni M
    Anticancer Res; 2009 Dec; 29(12):5111-9. PubMed ID: 20044624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients.
    Peng Z; Liu Y; Li Y; Zhang X; Zhou J; Lu M; Li Q; Shen L
    Biomark Med; 2014; 8(5):663-70. PubMed ID: 25123035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Utility of serum human epidermal growth factor receptor-2 extracellular domain(HER2 ECD)assessment in patients with advanced or recurrent breast cancer and those who received neoadjuvant therapy].
    Makino H; Iraha M; Manba N; Hashidate H; Shiotani M
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):237-40. PubMed ID: 22333634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.